NCT04557865View on ClinicalTrials.gov

Establishing 18F PMPBB3 (APN 1607) PET Imaging Markers for Diagnosis of Tauopathy Parkinsonism Syndromes

NACompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

September 2, 2024

Study Completion Date

September 2, 2024

Conditions
Tau Distributions in Patients With Tauopathy Using APN-1607 PET Scan
Interventions
DIAGNOSTIC_TEST

18F-PMPBB3 (APN-1607) PET imaging

"1. Name: 18F-PMPBB3 (APN-1607, MNI-958, or APN-0000455)~2. Dosage form: injection form~3. Strength: 5mCi/dose~4. Dosage and administration: 5mCi, intravenous injection~5. Mechanism of action (if known): bind to tau protein in the brain~6. Pharmacological category: radiopharamceutical"

Trial Locations (1)

Unknown

National Taiwan University Hospital, Taipei

All Listed Sponsors
lead

National Taiwan University Hospital

OTHER